

YMTHE, Volume 27

Supplemental Information

A Randomized, Double-Blind, Placebo-Controlled


Phase II Study of Hepatocyte Growth Factor

in the Treatment of Critical Limb Ischemia


Yongquan Gu, Shijun Cui, Qi Wang, Changjian Liu, Bi Jin, Wei Guo, Changwei Liu, Tongbin Chu, Chang Shu, Fuxian Zhang, Chengquan Han, and Yue Liu

Supplement Materials

Graph 1 Amputation Free Comparative Data



Graph 2 Legend of Injection Site



Legend of injections selection:32 injection sites marked with “x” were selected totally for each patients.
Each adjacent 8 injection sites were grouped, and the gap between injection sites was less than 2 cm.

Graph 3 Ulcer Healing on Days 0, 90 and 180

Photographs of ulceration area of two patients(A and B) were captured on days 0,90 and 180 for comparison

A:



D0

D90

D180

B:



D0

D90

D180

Table 1 Difference test between groups of anticoagulants or not

Using of anticoagulants	Placebo	Low dose	Medium dose	High dose
No	37	36	39	34
Yes	13	14	11	16
Statistic value	1.3191			
P-value	0.7246			

Table 2 Difference test between groups of drug combination

Using of anticoagulants and antiplatelet	Placebo	Low dose	Medium dose	High dose
No	41	40	44	42
Yes	9	10	6	8
Statistic value	1.2702			
P-value	0.7362			

Table 3 rate of complete pain relief in ASO patients			
group	N	Completely relief of pain, n (%)	P
Placebo	31	2(6.45)	
Low dose	33	16(48.48)	0.0005
Middle dose	30	16(53.33)	<0.0001
High dose	30	15(50.00)	0.0007

Table 4 rate of complete pain relief in TAO patients			
group	N	Completely relief of pain, n (%)	P
Placebo	15	1(6.67)	
Low dose	14	7(50.00)	0.014
Middle dose	18	11(61.11)	0.003
High dose	18	11(61.11)	0.003

Table5 rate of complete ulcer healing in ASO patients			
group	N	Completely healed of ulceration, n (%)	P
Placebo	14	2(14.29)	
Low dose	10	4(40.00)	0.3408
Middle dose	10	5(50.00)	0.0850
High dose	5	3(60.00)	0.0844

Table 6 rate of complete ulcer healing in TAO patients			
group	N	Completely healed of ulceration, n (%)	P
Placebo	8	4(50.00)	
Low dose	9	4(44.44)	1.0
Middle dose	13	7(53.85)	1.0
High dose	13	9(69.23)	0.6458